CA2195758A1 - Derives de l'acide phenoxyphenylacetique - Google Patents

Derives de l'acide phenoxyphenylacetique

Info

Publication number
CA2195758A1
CA2195758A1 CA002195758A CA2195758A CA2195758A1 CA 2195758 A1 CA2195758 A1 CA 2195758A1 CA 002195758 A CA002195758 A CA 002195758A CA 2195758 A CA2195758 A CA 2195758A CA 2195758 A1 CA2195758 A1 CA 2195758A1
Authority
CA
Canada
Prior art keywords
alkyl
propylphenoxy
nmr
ppm
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002195758A
Other languages
English (en)
Inventor
Scott W. Bagley
Theodore P. Broten
Prasun K. Chakravarty
Daljit S. Dhanoa
Kenneth J. Fitch
William J. Greenlee
Nancy Jo Kevin
Douglas J. Pettibone
Ralph A. Rivero
James R. Tata
Thomas F. Walsh
David L. Williams, Jr.
Richard B. Toupence
Jay M. Matthews
Gerard R. Kieczykowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/294,232 external-priority patent/US5565485A/en
Application filed by Individual filed Critical Individual
Publication of CA2195758A1 publication Critical patent/CA2195758A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Acide phénoxyphénylacétique et ses dérivés de formule générale (I) présentant une activité antagoniste de l'endothéline, et s'avérant utiles dans le traitement des troubles cardio-vasculaires tels que l'hypertension, l'insuffisance rénale postischémique, les angiospasmes, les ischémies cérébrales et coronarienne, l'infarctus du myocarde, le choc endotoxique, l'adénome prostatique, certains troubles inflammatoires dont la maladie de Raynaud et l'asthme.
CA002195758A 1994-08-08 1995-08-07 Derives de l'acide phenoxyphenylacetique Abandoned CA2195758A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28737494A 1994-08-08 1994-08-08
US08/294,232 US5565485A (en) 1993-03-19 1994-08-22 Biphenyl compounds useful or endothelin antagonists
US47317295A 1995-06-07 1995-06-07
US294,232 1995-06-07
US473,172 1995-06-07
US287,374 1995-06-07

Publications (1)

Publication Number Publication Date
CA2195758A1 true CA2195758A1 (fr) 1996-02-22

Family

ID=27403702

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002195758A Abandoned CA2195758A1 (fr) 1994-08-08 1995-08-07 Derives de l'acide phenoxyphenylacetique

Country Status (4)

Country Link
EP (1) EP0774965A4 (fr)
JP (1) JPH10503779A (fr)
CA (1) CA2195758A1 (fr)
WO (1) WO1996004905A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
AU703486B2 (en) * 1995-12-12 1999-03-25 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
WO1999048530A1 (fr) * 1998-03-23 1999-09-30 Merck & Co., Inc. Therapie combinee pour le traitement de l'hyperplasie prostatique benigne
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
NZ535603A (en) * 2002-03-20 2007-10-26 Metabolex Inc Substituted phenylacetic acids
WO2010137336A1 (fr) * 2009-05-29 2010-12-02 興和株式会社 NOUVEAU DÉRIVÉ D'ACIDE α-PHÉNOXYBENZÈNEACÉTIQUE ET PRÉPARATION PHARMACEUTIQUE LE CONTENANT
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
CA2804877A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
WO2012007877A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
CA2801032A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
CA2804716A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
WO2013088315A1 (fr) 2011-12-15 2013-06-20 Pfizer Limited Dérivés de sulfonamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69422742T2 (de) * 1993-03-19 2000-08-17 Merck & Co Inc Phenoxyphenylessigsäurederivate
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides

Also Published As

Publication number Publication date
WO1996004905A1 (fr) 1996-02-22
JPH10503779A (ja) 1998-04-07
EP0774965A1 (fr) 1997-05-28
EP0774965A4 (fr) 1997-10-29

Similar Documents

Publication Publication Date Title
US5565485A (en) Biphenyl compounds useful or endothelin antagonists
AU679710B2 (en) Phenoxyphenylacetic acid derivatives
WO1996009818A1 (fr) Antagonistes du recepteur d'endotheline utilises dans le traitement des vomissements
US5538991A (en) Endothelin antagonists bearing 5-membered heterocyclic amides
WO1995003044A1 (fr) Benzimidazolinones a substitution par des derives d'acide phenoxyphenylacetique
CA2195758A1 (fr) Derives de l'acide phenoxyphenylacetique
US5559135A (en) Endothelin antagonists bearing pyridyl amides
US20030114447A1 (en) Small molecule inhibitors of caspases
WO1994021255A1 (fr) Imidazoles fusionnes a anneau hexaedrique substitues par des derives d'acide phenoxyphenylacetique
CA2561897C (fr) Derives de biaryl-methanesulfinyle substitues par thio
KR20000057576A (ko) 설폰아미드 및 카르보아미드 유도체와, 이들을 유효 성분으로함유하는 약제
US5686478A (en) Endothelin antagonists
US5401745A (en) Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5767310A (en) Phenoxyphenylacetic acid derivatives
US20030181766A1 (en) Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them
AU705881B2 (en) Phenoxyphenylacetic acid derivatives
EP1283825B1 (fr) Utilisation de peptidyl nitriles a substitution- n comme inhibiteurs des cathepsines de cysteine
CA2308478C (fr) Derive indolique utile comme antagoniste de recepteur d'endotheline

Legal Events

Date Code Title Description
FZDE Dead